Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 3
1994 1
2001 1
2002 1
2006 4
2007 2
2008 1
2010 2
2011 1
2012 1
2014 2
2015 3
2017 2
2018 2
2019 5
2020 9
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Results by year
Filters applied: . Clear all
Page 1
An overview of the safety pharmacology society strategic plan.
Pugsley MK, Authier S, Koerner JE, Redfern WS, Markgraf CG, Brabham T, Correll K, Soloviev MV, Botchway A, Engwall M, Traebert M, Valentin JP, Mow TJ, Greiter-Wilke A, Leishman DJ, Vargas HM. Pugsley MK, et al. Among authors: leishman dj. J Pharmacol Toxicol Methods. 2018 Sep-Oct;93:35-45. doi: 10.1016/j.vascn.2018.01.001. Epub 2018 Jan 9. J Pharmacol Toxicol Methods. 2018. PMID: 29330132 Review.
Gastrointestinal Safety Pharmacology in Drug Discovery and Development.
Al-Saffar A, Nogueira da Costa A, Delaunois A, Leishman DJ, Marks L, Rosseels ML, Valentin JP. Al-Saffar A, et al. Among authors: leishman dj. Handb Exp Pharmacol. 2015;229:291-321. doi: 10.1007/978-3-662-46943-9_12. Handb Exp Pharmacol. 2015. PMID: 26091645 Review.
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Vargas HM, Rolf MG, Wisialowski TA, Achanzar W, Bahinski A, Bass A, Benson CT, Chaudhary KW, Couvreur N, Dota C, Engwall MJ, Michael Foley C, Gallacher D, Greiter-Wilke A, Guillon JM, Guth B, Himmel HM, Hegele-Hartung C, Ito M, Jenkinson S, Chiba K, Lagrutta A, Levesque P, Martel E, Okai Y, Peri R, Pointon A, Qu Y, Teisman A, Traebert M, Yoshinaga T, Gintant GA, Leishman DJ, Valentin JP. Vargas HM, et al. Among authors: leishman dj. Clin Pharmacol Ther. 2021 Feb;109(2):310-318. doi: 10.1002/cpt.2029. Epub 2020 Sep 24. Clin Pharmacol Ther. 2021. PMID: 32866317 Free PMC article. Review.
A Bayesian approach to toxicological testing.
Felli JC, Leishman DJ. Felli JC, et al. Among authors: leishman dj. J Pharmacol Toxicol Methods. 2020 Sep;105:106898. doi: 10.1016/j.vascn.2020.106898. Epub 2020 Jul 29. J Pharmacol Toxicol Methods. 2020. PMID: 32735877
The Safety Pharmacology Society salary survey.
Pugsley MK, Authier S, Brabham T, Soloviev M, Markgraf CG, Correll K, Traebert M, Greiter-Wilke A, Valentin JP, Vargas H, Botchway A, Leishman DJ, Curtis MJ. Pugsley MK, et al. Among authors: leishman dj. J Pharmacol Toxicol Methods. 2017 Nov;88(Pt 1):85-91. doi: 10.1016/j.vascn.2017.08.002. Epub 2017 Aug 7. J Pharmacol Toxicol Methods. 2017. PMID: 28797763
Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium.
Heller S, Darpö B, Mitchell MI, Linnebjerg H, Leishman DJ, Mehrotra N, Zhu H, Koerner J, Fiszman ML, Balakrishnan S, Xiao S, Todaro TG, Hensley I, Guth BD, Michelson EL, Sager P. Heller S, et al. Among authors: leishman dj. Am Heart J. 2015 Jul;170(1):23-35. doi: 10.1016/j.ahj.2015.03.007. Epub 2015 Mar 18. Am Heart J. 2015. PMID: 26093861 Review.
Improving corrected QT; Why individual correction is not enough.
Ether ND, Jantre SR, Sharma DB, Leishman DJ, Bailie MB, Lauver DA. Ether ND, et al. Among authors: leishman dj. J Pharmacol Toxicol Methods. 2022 Jan-Feb;113:107126. doi: 10.1016/j.vascn.2021.107126. Epub 2021 Oct 13. J Pharmacol Toxicol Methods. 2022. PMID: 34655760 Free article.
Is there a role for the no observed adverse effect level in safety pharmacology?
Mow T, Andersen NK, Dragsted N, Lassen AB, Laursen M, Bass AS, Valentin JP, Markgraf C, Authier S, Baird TJ, Bhatt S, Traebert M, Leishman DJ, Jones D, Curtis MJ. Mow T, et al. Among authors: leishman dj. J Pharmacol Toxicol Methods. 2020 Sep;105:106917. doi: 10.1016/j.vascn.2020.106917. Epub 2020 Aug 29. J Pharmacol Toxicol Methods. 2020. PMID: 32866658
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm.
Ridder BJ, Leishman DJ, Bridgland-Taylor M, Samieegohar M, Han X, Wu WW, Randolph A, Tran P, Sheng J, Danker T, Lindqvist A, Konrad D, Hebeisen S, Polonchuk L, Gissinger E, Renganathan M, Koci B, Wei H, Fan J, Levesque P, Kwagh J, Imredy J, Zhai J, Rogers M, Humphries E, Kirby R, Stoelzle-Feix S, Brinkwirth N, Rotordam MG, Becker N, Friis S, Rapedius M, Goetze TA, Strassmaier T, Okeyo G, Kramer J, Kuryshev Y, Wu C, Himmel H, Mirams GR, Strauss DG, Bardenet R, Li Z. Ridder BJ, et al. Among authors: leishman dj. Toxicol Appl Pharmacol. 2020 May 1;394:114961. doi: 10.1016/j.taap.2020.114961. Epub 2020 Mar 21. Toxicol Appl Pharmacol. 2020. PMID: 32209365 Free PMC article.
38 results